RBC Capital raised the firm’s price target on Ascendis Pharma (ASND) to $210 from $205 and keeps an Outperform rating on the shares. The company reported Q1 with a strong beat for Yorvipath, and in the US, the over 1,750 prescriptions came ahead of the 1,500 bogey that the firm has been hearing from investors, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma price target raised to $212 from $181 at Wedbush
- Ascendis Pharma price target raised to $245 from $200 at JPMorgan
- Ascendis Pharma’s Yorvipath Drives Strong US Market Performance and Promising Long-term Outlook, Justifying Buy Rating
- Ascendis Pharma Reports Strong Q1 2025 Performance
- Promising Growth and Investment Potential for Ascendis Pharma Amid Strong Yorvipath Launch and Upcoming Catalysts